The team created the tool to spur drug discovery. The researchers view discontinued agents as an untapped resource for antibiotics and believe they can be used to circumvent the spread of antibiotic resistance.
The database includes data on discovery, research, clinical trials and compounds awaiting approval. It also includes discontinued compounds, some dating back to the 1960s. The tool also provides information on why the development was discontinued.
The database was spearheaded Laura Piddock, PhD, a professor of microbiology with the University of Birmingham, and scientists from the John Innes Centre in Norwich, England.
“We wanted to establish the current status of the drug-discovery pipeline in antibiotic development — particularly to look at compounds that might have been dropped in the past to see if they could be resuscitated,” said Tony Maxwell, PhD, a study author and project leader in biological chemistry with the John Innes Centre.
More articles on healthcare quality:
Eye exam instruments linked to adenovirus outbreak in NICU
Human tracking of hand hygiene compliance inadequate
American Academy of Pediatrics releases new guidelines for infertility discussion with younger patients
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.